GSK (GSK) Competitors GBX 1,479.50 -13.00 (-0.87%) As of 08/22/2025 12:38 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesSustainabilityBuy This Stock GSK vs. AZN, ITH, SOPH, HCM, INDV, GRI, SLS, ERGO, SLN, and AMYTShould you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), HUTCHMED (HCM), Indivior (INDV), Grainger (GRI), Standard Life UK Smaller Companies Trust (SLS), Ergomed (ERGO), Silence Therapeutics (SLN), and Amryt Pharma (AMYT). These companies are all part of the "pharmaceutical products" industry. GSK vs. Its Competitors AstraZeneca Ithaca Energy Sophos Group plc (SOPH.L) HUTCHMED Indivior Grainger Standard Life UK Smaller Companies Trust Ergomed Silence Therapeutics Amryt Pharma AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Is AZN or GSK more profitable? AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.Company Net Margins Return on Equity Return on Assets AstraZeneca13.01% 17.76% 7.68% GSK 8.02%18.08%9.56% Which has more volatility and risk, AZN or GSK? AstraZeneca has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Which has better earnings and valuation, AZN or GSK? AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstraZeneca£66.95B3.44£8.71B£364.8332.79GSK£31.14B1.93£2.50B£61.9123.90 Do analysts recommend AZN or GSK? AstraZeneca currently has a consensus price target of GBX 9,660, suggesting a potential downside of 19.25%. GSK has a consensus price target of GBX 1,612.50, suggesting a potential upside of 8.99%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than AstraZeneca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AstraZeneca 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75GSK 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals believe in AZN or GSK? 51.0% of AstraZeneca shares are owned by institutional investors. Comparatively, 45.3% of GSK shares are owned by institutional investors. 0.0% of AstraZeneca shares are owned by company insiders. Comparatively, 1.6% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor AZN or GSK? In the previous week, AstraZeneca had 6 more articles in the media than GSK. MarketBeat recorded 10 mentions for AstraZeneca and 4 mentions for GSK. GSK's average media sentiment score of 0.40 beat AstraZeneca's score of 0.15 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GSK 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is AZN or GSK a better dividend stock? AstraZeneca pays an annual dividend of GBX 234 per share and has a dividend yield of 2.0%. GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 4.1%. AstraZeneca pays out 64.1% of its earnings in the form of a dividend. GSK pays out 96.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. SummaryAstraZeneca beats GSK on 11 of the 18 factors compared between the two stocks. Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GSK vs. The Competition Export to ExcelMetricGSKDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£60.04B£87.15B£5.80B£3.22BDividend Yield4.25%2.50%4.40%5.04%P/E Ratio23.9025.3931.43164.70Price / Sales1.93179.07472.41310,111.42Price / Cash8.1517.5925.7827.93Price / Book4.493.329.525.91Net Income£2.50B£3.43B£3.26B£5.89B7 Day Performance2.92%1.10%1.37%49.44%1 Month Performance6.25%8.44%2.97%58.03%1 Year Performance-7.68%9.39%30.23%141.20% GSK Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GSKGSK1.8928 of 5 starsGBX 1,479.50-0.9%GBX 1,612.50+9.0%-7.7%£60.04B£31.14B23.9070,212AZNAstraZeneca2.1451 of 5 stars£117.18-0.2%GBX 9,660-17.6%-8.5%£225.46B£66.95B32.1283,500High Trading VolumeITHIthaca EnergyN/AGBX 178+0.7%N/A+73.2%£3.71B£3.55B20.33220News CoverageSOPHSophos Group plc (SOPH.L)N/AN/AN/AN/A£2.99B£726.90M341.41520HCMHUTCHMEDN/AGBX 241+2.6%N/A-9.1%£2.62B£771.01M-61.511,760News CoverageINDVIndivior2.4631 of 5 starsGBX 1,238+1.6%GBX 1,650+33.3%+33.8%£1.93B£1.40B-1,026.481,000Gap UpHigh Trading VolumeGRIGrainger2.6943 of 5 starsGBX 199.96+0.2%GBX 317.50+58.8%-18.8%£1.48B£276.05M-1,333.07372Dividend IncreaseSLSStandard Life UK Smaller Companies TrustN/AN/AN/AN/A£715.41M£222.48M3.3710ERGOErgomedN/AN/AN/AN/A£701.00M£152.09M4,641.386SLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumeAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down Related Companies and Tools Related Companies AZN Competitors ITH Competitors SOPH Competitors HCM Competitors INDV Competitors GRI Competitors SLS Competitors ERGO Competitors SLN Competitors AMYT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:GSK) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.